{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:49:47Z","timestamp":1794620987312,"version":"4.9.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A wide range of advanced therapies has become available in recent years for the treatment of moderate-to-severe inflammatory bowel disease (IBD). Among these, monoclonal antibodies targeting the interleukin 23 p19 subunit (anti-IL23p19) have emerged as a promising therapeutic class. Pivotal Phase 3 trials have demonstrated their favorable clinical efficacy and safety in both Crohn\u2019s disease (CD) and ulcerative colitis (UC). Three such agents, Risankizumab, Mirikizumab, and Guselkumab, have now been approved in CD and UC. For gastroenterologists, the ability to rationally select among these options to personalize treatment and maximize patient benefit is critical. Key factors to consider when selecting an anti-IL23p19 agent include patient preference regarding mode of administration, IBD phenotype, presence of coexisting extra-intestinal manifestations, concomitant immune-mediated diseases, and previous advanced-therapy exposure. Our review summarizes the current clinical evidence on anti-IL23p19 therapies and provides practical guidance on their use in IBD clinical management, including dosing strategies, choice of dose in CD and UC, and clinical positioning across patients. Finally, anti-IL23p19 inhibition may represent a future first-line therapy option for moderate-to-severe IBD, particularly in patients with concomitant IL-23 driven comorbidities such as psoriasis. Its use in combination with other advanced therapies in selected patients is being explored to enhance therapeutic efficacy and improve long-term outcomes. Further real-world studies are needed to assess its effectiveness and benefits in complex disease phenotypes, including perianal fistulizing Crohn\u2019s disease.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf144","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:57:01Z","timestamp":1754049421000},"source":"Crossref","is-referenced-by-count":17,"title":["Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6043-3231","authenticated-orcid":false,"given":"Cecilia Lina","family":"Pugliano","sequence":"first","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Fueng-Hin","family":"Liang","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruffa","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-9550","authenticated-orcid":false,"given":"Marietta","family":"Iacucci","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-7797","authenticated-orcid":false,"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2025091915112817700_jjaf144-B1","doi-asserted-by":"publisher","first-page":"II64","DOI":"10.1093\/ECCO-JCC\/JJAB185","article-title":"Blockade of IL-23: what is in the pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025091915112817700_jjaf144-B2","doi-asserted-by":"publisher","first-page":"II3","DOI":"10.1093\/ECCO-JCC\/JJAC034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025091915112817700_jjaf144-B3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2022.07.005","article-title":"The involvement of TH17 cells in the pathogenesis of IBD","volume":"69","author":"Jiang","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"2025091915112817700_jjaf144-B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/J.GASTRO.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"2025091915112817700_jjaf144-B5","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMOA1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMOA1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B7","doi-asserted-by":"publisher","first-page":"1532852","DOI":"10.3389\/FIMMU.2025.1532852","article-title":"Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling","volume":"16","author":"Sachen","year":"2025","journal-title":"Front Immunol."},{"key":"2025091915112817700_jjaf144-B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025091915112817700_jjaf144-B9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/BTT.S530354","article-title":"Positioning Guselkumab in the treatment algorithm of patients with crohn\u2019s Disease","volume":"19","author":"D'Amico","year":"2025","journal-title":"Biologics."},{"key":"2025091915112817700_jjaf144-B10","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMOA2207940\/SUPPL_FILE\/NEJMOA2207940_DATA-SHARING.PDF","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/JAMA.2024.12414","article-title":"Risankizumab for ulcerative colitis","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"2025091915112817700_jjaf144-B13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/J.GASTRO.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2025091915112817700_jjaf144-B17"},{"key":"2025091915112817700_jjaf144-B18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/J.GASTRO.2025.02.033","article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 graviti study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"2025091915112817700_jjaf144-B19"},{"key":"2025091915112817700_jjaf144-B20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"The Lancet"},{"key":"2025091915112817700_jjaf144-B21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMOA2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMOA1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/S00535-024-02130-X","article-title":"Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment\u2014insights from Phase II and III trials","volume":"59","author":"Massironi","year":"2024","journal-title":"J Gastroenterol."},{"key":"2025091915112817700_jjaf144-B24","author":"Peyrin-Biroulet"},{"key":"2025091915112817700_jjaf144-B25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet."},{"key":"2025091915112817700_jjaf144-B28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMOA1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med."},{"key":"2025091915112817700_jjaf144-B29","author":"Information"},{"key":"2025091915112817700_jjaf144-B30","doi-asserted-by":"publisher","DOI":"10.1093\/IBD\/IZAF113","article-title":"First documented case of successful dual therapy with upadacitinib and mirikizumab for multi-refractory ulcerative proctitis","author":"Robles de la Osa","year":"2025","journal-title":"Inflamm Bowel Dis."},{"key":"2025091915112817700_jjaf144-B31","doi-asserted-by":"publisher","first-page":"17562848241272995","DOI":"10.1177\/17562848241272995","article-title":"Advanced combination therapy: is it the best way to break the therapeutic ceiling?","volume":"17","author":"Wetwittayakhlang","year":"2024","journal-title":"Therap Adv Gastroenterol."},{"key":"2025091915112817700_jjaf144-B32","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/J.BPG.2025.101981","article-title":"Reaching the therapeutic ceiling in IBD: can advanced combination treatment (ACT) offer a solution?","volume":"77","author":"Solitano","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025091915112817700_jjaf144-B33","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2025091915112817700_jjaf144-B34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025091915112817700_jjaf144-B35"},{"key":"2025091915112817700_jjaf144-B36"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf144\/63920109\/jjaf144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf144\/63920109\/jjaf144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/8\/jjaf144\/63920109\/jjaf144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:11:33Z","timestamp":1758309093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf144\/8220916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf144","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,8,1]]},"article-number":"jjaf144"}}